Integrated Biotherapeutics, Inc.

Leland Stanford Junior University

University System of Maryland

Integral Molecular, Inc.

Razi Holdings, Inc.

Katie A Howell

Mohammad Javad Aman

Frederick Wayne Holtsberg

Benjamin J Doranz

Yuxing Li

Zhen-Yong Keck

Steven K H Foung

Xuelian Zhao

Edgar Davidson

Sven G Enterlein

This disclosure provides a method for preventing, treating, or managing an ebolavirus infection in a subject, where the method includes administering to a subject in need thereof an effective amount of at least one pan-ebolavirus internal fusion loop antibody or antigen-binding fragment thereof, wherein the binding domain specifically binds to the epitope on two or more ebolavirus species or strains.

Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop

Provided herein are methods of incorporating substitutions of specified residues into a filovirus GP in order to increase immunogenicity and/or broaden the cross-reactivity of the protective immune response against other filovirus members. Also provided herein are mutant filovirus GPs comprising such substitutions.

Modified ebolavirus glycoproteins comprising mutations in the head and base domains that increase antibody cross-reactivity

The disclosure provides non-human primate-derived binding molecules, e.g., antibodies or antigen-binding fragments thereof, that can bind to orthologous epitopes found on two or more filovirus species or strains.

Non-human primate-derived pan-ebola and pan-filovirus monoclonal antibodies directed against envelope glycoproteins

Growing community of inventors

North Bethesda, MD, United States of America

Katie A Howell